These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 24462742)

  • 41. Hematopoietic stem cell transplantation in children and young adults with secondary myelodysplastic syndrome and acute myelogenous leukemia after aplastic anemia.
    Yoshimi A; Strahm B; Baumann I; Furlan I; Schwarz S; Teigler-Schlegel A; Walther JU; Schlegelberger B; Göhring G; Nöllke P; Führer M; Niemeyer CM
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):425-9. PubMed ID: 24316460
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High-dose chemotherapy with busulfan and cyclophosphamide and autologous stem cell rescue in patients with Hodgkin lymphoma.
    Lane AA; McAfee SL; Kennedy J; Dube C; Attar EC; Ballen KK; Dey BR; Spitzer TR; Chen YB
    Leuk Lymphoma; 2011 Jul; 52(7):1363-6. PubMed ID: 21612379
    [No Abstract]   [Full Text] [Related]  

  • 43. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine.
    Lee JH; Joo YD; Kim H; Ryoo HM; Kim MK; Lee GW; Lee JH; Lee WS; Park JH; Bae SH; Hyun MS; Kim DY; Kim SD; Min YJ; Lee KH
    J Clin Oncol; 2013 Feb; 31(6):701-9. PubMed ID: 23129746
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Optimizing the pretransplant regimen for autologous stem cell transplantation in acute myelogenous leukemia: Better outcomes with busulfan and melphalan compared with busulfan and cyclophosphamide in high risk patients autografted in first complete remission: A study from the acute leukemia working party of the EBMT.
    Gorin NC; Labopin M; Blaise D; Dumas PY; Pabst T; Trisolini SM; Arcese W; Houhou M; Mohty M; Nagler A
    Am J Hematol; 2018 Jul; 93(7):859-866. PubMed ID: 29644709
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency.
    Al-Mousa H; Al-Shammari Z; Al-Ghonaium A; Al-Dhekri H; Al-Muhsen S; Al-Saud B; Arnaout R; Al-Seraihy A; Al-Jefri A; Al-Ahmari A; Ayas M; El-Solh H
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):818-23. PubMed ID: 20079864
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hematopoietic stem cell transplantation (HSCT) with a conditioning regimen of busulfan, cyclophosphamide, and etoposide for children with acute myelogenous leukemia (AML): a phase I study of the Pediatric Blood and Marrow Transplant Consortium.
    Sandler ES; Hagg R; Coppes MJ; Mustafa MM; Gamis A; Kamani N; Wall D
    Med Pediatr Oncol; 2000 Oct; 35(4):403-9. PubMed ID: 11025470
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML.
    Horn B; Baxter-Lowe LA; Englert L; McMillan A; Quinn M; Desantes K; Cowan M
    Bone Marrow Transplant; 2006 Feb; 37(3):263-9. PubMed ID: 16327813
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
    Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH
    Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reduced-toxicity conditioning regimen with busulfan, fludarabine, rATG, and 400 cGy TBI in pediatric patients undergoing hematopoietic stem cell transplant for high-risk hematologic malignancies.
    Rossoff J; Jacobsohn D; Kwon S; Kletzel M; Duerst RE; Tse WT; Schneiderman J; Chaudhury S
    Pediatr Blood Cancer; 2021 Aug; 68(8):e29087. PubMed ID: 34022093
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes.
    Rezvani AR; McCune JS; Storer BE; Batchelder A; Kida A; Deeg HJ; McDonald GB
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1033-9. PubMed ID: 23583825
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bone marrow transplantation for non-malignant diseases using treosulfan-based conditioning.
    Dinur-Schejter Y; Krauss AC; Erlich O; Gorelik N; Yahel A; Porat I; Weintraub M; Stein J; Zaidman I; Stepensky P
    Pediatr Blood Cancer; 2015 Feb; 62(2):299-304. PubMed ID: 25284797
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of conditioning regimens for autologous stem cell transplantation in children with acute myeloid leukemia: A nationwide retrospective study in Japan.
    Sakaguchi H; Muramatsu H; Hasegawa D; Kudo K; Ishida H; Yoshida N; Koh K; Noguchi M; Shiba N; Tokimasa S; Fukuda T; Goto H; Miyamura T; Nakazawa Y; Hashii Y; Inoue M; Atsuta Y;
    Pediatr Blood Cancer; 2019 Jan; 66(1):e27459. PubMed ID: 30270523
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Acute toxicity and outcome among pediatric allogeneic hematopoietic transplant patients conditioned with treosulfan-based regimens.
    Huttunen P; Taskinen M; Vettenranta K
    Pediatr Hematol Oncol; 2020 Aug; 37(5):355-364. PubMed ID: 32166994
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
    Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning.
    Kanakry CG; O'Donnell PV; Furlong T; de Lima MJ; Wei W; Medeot M; Mielcarek M; Champlin RE; Jones RJ; Thall PF; Andersson BS; Luznik L
    J Clin Oncol; 2014 Nov; 32(31):3497-505. PubMed ID: 25267759
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fludarabine-based reduced intensity conditioning for stem cell transplantation of Fanconi anemia patients from fully matched related and unrelated donors.
    Bitan M; Or R; Shapira MY; Aker M; Resnick IB; Ackerstein A; Samuel S; Elad S; Slavin S
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):712-8. PubMed ID: 16785060
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation.
    Brunstein CG; Pasquini MC; Kim S; Fei M; Adekola K; Ahmed I; Aljurf M; Agrawal V; Auletta JJ; Battiwalla M; Bejanyan N; Bubalo J; Cerny J; Chee L; Ciurea SO; Freytes C; Gadalla SM; Gale RP; Ganguly S; Hashmi SK; Hematti P; Hildebrandt G; Holmberg LA; Lahoud OB; Landau H; Lazarus HM; de Lima M; Mathews V; Maziarz R; Nishihori T; Norkin M; Olsson R; Reshef R; Rotz S; Savani B; Schouten HC; Seo S; Wirk BM; Yared J; Mineishi S; Rogosheske J; Perales MA
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):480-487. PubMed ID: 30423481
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of Dose-Adjusted Melphalan in Obese Patients Undergoing Autologous Stem Cell Transplantation.
    Shultes KC; Arp C; Stockerl-Goldstein K; Trinkaus K; DeFrates S
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):687-693. PubMed ID: 29225163
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis.
    Nash RA; McSweeney PA; Nelson JL; Wener M; Georges GE; Langston AA; Shulman H; Sullivan KM; Lee J; Henstorf G; Storb R; Furst DE
    Arthritis Rheum; 2006 Jun; 54(6):1982-6. PubMed ID: 16732546
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation.
    Perkins JB; Kim J; Anasetti C; Fernandez HF; Perez LE; Ayala E; Kharfan-Dabaja MA; Tomblyn MR; Sullivan DM; Pidala JA; Field TL
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1099-107. PubMed ID: 22198540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.